Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (42927)	11/14/2005 8:13:19 AM
From: CusterInvestor	Respond to of 120411

Nice call on AVAN Gary, between AVII in Barrons and this we may see a rebound in the bird flu stocks this week.

To: GARY P GROBBEL who wrote (42927)	11/14/2005 10:05:33 AM
From: rrufff	Read Replies (1) \| Respond to of 120411

AVAN 1.60 +.14 - been sitting on this one for so long, I even took it off my daily watch list. IMO much better run and scientific company than GNBT which continues to look very strong.

To: GARY P GROBBEL who wrote (42927)	11/14/2005 1:38:17 PM
From: rrufff	Read Replies (2) \| Respond to of 120411

AVAN 1.71 + .25 - nice call AP Avant Stock Climbs on Bird Flu Initiative Monday November 14, 11:31 am ET Avant Immunotherapeutics Shares Climb As Vaccine Maker Devotes Resources to Bird Flu NEEDHAM, Mass. (AP) -- Avant Immunotherapeutics Inc. shares climbed Monday after the vaccine maker said it was devoting resources for the development of a mass-scale bird flu vaccine. Shares of Avant rose 16 cents, or 10.7 percent, to $1.62 in morning trading on the Nasdaq. Shares have traded between $1.09 and $2.47 in the past 52 weeks. The company said it formed a research team to focus on the development of a bird flu vaccine that can be kept at room temperature using its virus vector and preservation technologies. Avant said the effort and others will be funded by the $50 million generated by the May sale of rotavirus vaccine Rotarix rights to Paul Royalty Fund II.